ZNTL — Zentalis Pharmaceuticals Inc · catalysts, narrative & risks

Overview and Recent Trading Context

As of the close on October 29, 2026, ZNTL traded at $1.99, down 3.40% for the day, with extended-trading prices around $2.00–$2.02 [6]. On a market-cap basis, the company was valued at roughly USD 185.4 million as of October 1, 2026, within a 52-week price range of USD 1.21 to USD 6.95 [2]. (This is consistent with, though not an exact confirmation of, the prior-knowledge snapshot of ~$195.26M dated October 30, 2026.) The company is a clinical-stage oncology developer whose lead candidate is azenosertib, an oral WEE1 inhibitor [3][5].

Recent Catalysts (July–October 2026)